Consolidation Treatment with VRD improves PFS and deep response in Newly Diagnosed Patients with Multiple Myeloma
In this MEDtalk, the world-leading expert in multiple myeloma, Professor Pieter Sonneveld, presents the result of the final analysis phase 3 trial of the European Myeloma Network of VRD consolidation therapy followed by lenalidomide in patients with Newly Diagnosed Multiple Myeloma. The study shows that VRD consolidation therapy followed by lenalidomide improves PFS and depth of response.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.